Buy Like Buffett
Watchlist

Flagship explainer

How AKEBIA THERAPEUTICS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$236M · 100%Cost of revenue$39.5M · 17%Gross profit$197M · 83%Operating income$23.5M · 10%Income before tax−$3.7M · −2%Income tax$1.6M · 1%Net income−$5.3M · −2%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$236M100%
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
Cost of revenue$39.5M17%
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
$197M83%
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
$23.5M10%
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
Income before tax−$3.7M−2%
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
Income tax$1.6M1%
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
−$5.3M−2%
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001517022-26-000020 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full AKEBIA THERAPEUTICS, INC. analysis at Buy Like Buffett